Skip to main content

Table 2 Postdosimetric parameters (all patients: n = 200)

From: Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer

 

Bounce (-) (n=150)

Bounce (+) (n=50)

P value

(mean ± SD)

(mean ± SD)

(t-test)

Prostate volume at postdosimetry (mL)

27.3 ± 8.7

29.0 ± 8.9

0.233

%D90 (%)

110.6 ± 9.9

109.7 ± 9.1

0.577

D90 (Gy)

152.3 ± 24.5

153.3 ± 19.4

0.772

V100 (%)

93.7 ± 3.6

93.5 ± 3.6

0.700

V150 (%)

62.3 ± 10.4

62.1 ± 10.3

0.881

R100 (mL)

0.10 ± 0.19

0.08 ± 0.10

0.668

Urethral volume (mL)

0.53 ± 0.28

0.41 ± 0.23

0.004

%UD90 (%)

97.6 ± 12.8

101.8 ± 12.7

0.049

UD90 (Gy)

134.1 ± 24.5

142.5 ± 23.6

0.035

%UD30 (%)

140.2 ± 18.0

143.8 ± 22.3

0.256

Minimal urethral dose (Gy)

100.9 ± 21.6

111.3 ± 22.2

0.004

BED (Gy2)

188.5 ± 25.2

177.0 ± 23.2

0.005